Jorge Barriuso
@drjorgebarriuso.bsky.social
Consultant (clinician-scientist) in medical oncology with an interest in Lower GI malignancies including appendix tumours and peritoneal metastasis. #H12O #imas12 #rarecancers #translationalresearch #drugdevelopment
Reposted by Jorge Barriuso
🎉 50 years. 50,000 professionals. Advancing #oncology
🤝 A #GlobalCommunity of #OncologyProfessionals growing, collaborating and innovating through ESMO.
Together, we continue to turn progress into lasting impact, improving care for #PatientsWithCancer
🤝 A #GlobalCommunity of #OncologyProfessionals growing, collaborating and innovating through ESMO.
Together, we continue to turn progress into lasting impact, improving care for #PatientsWithCancer
December 29, 2025 at 1:01 PM
🎉 50 years. 50,000 professionals. Advancing #oncology
🤝 A #GlobalCommunity of #OncologyProfessionals growing, collaborating and innovating through ESMO.
Together, we continue to turn progress into lasting impact, improving care for #PatientsWithCancer
🤝 A #GlobalCommunity of #OncologyProfessionals growing, collaborating and innovating through ESMO.
Together, we continue to turn progress into lasting impact, improving care for #PatientsWithCancer
Reposted by Jorge Barriuso
#ESMOImmuno25 Awardee, Ignacio Melero, discusses how current #immunotherapy can be improved upon with the use of synergistic approaches including combination therapies and targeting resistance mechanisms. Full interview in the #ESMODailyReporter 👉 https://ow.ly/bgun50XGRUt
December 10, 2025 at 2:32 PM
#ESMOImmuno25 Awardee, Ignacio Melero, discusses how current #immunotherapy can be improved upon with the use of synergistic approaches including combination therapies and targeting resistance mechanisms. Full interview in the #ESMODailyReporter 👉 https://ow.ly/bgun50XGRUt
Reposted by Jorge Barriuso
'Neoadjuvant immunotherapy continues to rewrite our understanding of anticancer immunity'
Check out my #ESMODailyReporter editorial on some of the abstracts presented at this year's #ESMOImmuno25 in London 👇
Check out my #ESMODailyReporter editorial on some of the abstracts presented at this year's #ESMOImmuno25 in London 👇
#ESMODailyReporter: Jon Lim, MRCP PhD discusses the use of single-cell spatial transcriptomics and proteomic profiling to dissect why #immunotherapy works in some tumours but not others, highlighting neoadjuvant studies at #ESMOImmuno25 #ImmunoOncology
➡️ https://ow.ly/kwgt50XGX4M
➡️ https://ow.ly/kwgt50XGX4M
December 10, 2025 at 5:07 PM
'Neoadjuvant immunotherapy continues to rewrite our understanding of anticancer immunity'
Check out my #ESMODailyReporter editorial on some of the abstracts presented at this year's #ESMOImmuno25 in London 👇
Check out my #ESMODailyReporter editorial on some of the abstracts presented at this year's #ESMOImmuno25 in London 👇
Reposted by Jorge Barriuso
#ESMOImmuno25: Encouraging data reported with the PD-L1/TGF-β-targeting bifunctional fusion protein, SHR-1701, added to first-line CAPOX in an analysis of patients with #GastricCancer and high-risk features. More info in the #ESMODailyReporter ➡️ https://ow.ly/WF1450XHmqY
December 11, 2025 at 12:30 PM
#ESMOImmuno25: Encouraging data reported with the PD-L1/TGF-β-targeting bifunctional fusion protein, SHR-1701, added to first-line CAPOX in an analysis of patients with #GastricCancer and high-risk features. More info in the #ESMODailyReporter ➡️ https://ow.ly/WF1450XHmqY
Reposted by Jorge Barriuso
#ESMOImmuno25: The next-generation PRAME-directed TCR T-cell therapy, IMA203CD8, showed encouraging activity not only in melanoma, but also in #OvarianCarcinoma and synovial sarcoma in a phase I #ClinicalTrial. Find out more in the #ESMODailyReporter ➡️ https://ow.ly/m30F50XHmHM
December 11, 2025 at 1:10 PM
#ESMOImmuno25: The next-generation PRAME-directed TCR T-cell therapy, IMA203CD8, showed encouraging activity not only in melanoma, but also in #OvarianCarcinoma and synovial sarcoma in a phase I #ClinicalTrial. Find out more in the #ESMODailyReporter ➡️ https://ow.ly/m30F50XHmHM
Reposted by Jorge Barriuso
#ESMOImmuno25: Mature overall survival data from the phase III POD1UM-303/InterAACT-2 #ClinicalTrial confirm the benefits of retifanlimab plus chemotherapy in the treatment of advanced squamous cell #AnalCancer.
Read more #ESMODailyReporter ➡️ https://ow.ly/rPN850XHmSL
Read more #ESMODailyReporter ➡️ https://ow.ly/rPN850XHmSL
December 11, 2025 at 2:30 PM
#ESMOImmuno25: Mature overall survival data from the phase III POD1UM-303/InterAACT-2 #ClinicalTrial confirm the benefits of retifanlimab plus chemotherapy in the treatment of advanced squamous cell #AnalCancer.
Read more #ESMODailyReporter ➡️ https://ow.ly/rPN850XHmSL
Read more #ESMODailyReporter ➡️ https://ow.ly/rPN850XHmSL
Reposted by Jorge Barriuso
The groundbreaking work behind the development of TCR mimics − ‘minibinders’ − is described by Sine Reker Hadrup in her Keynote Lecture at #ESMOImmuno25 and in an Opinion piece in the #ESMODailyReporter #ImmunoOncology
👉 https://ow.ly/jH9x50XHyFI
👉 https://ow.ly/jH9x50XHyFI
December 12, 2025 at 10:20 AM
The groundbreaking work behind the development of TCR mimics − ‘minibinders’ − is described by Sine Reker Hadrup in her Keynote Lecture at #ESMOImmuno25 and in an Opinion piece in the #ESMODailyReporter #ImmunoOncology
👉 https://ow.ly/jH9x50XHyFI
👉 https://ow.ly/jH9x50XHyFI
Reposted by Jorge Barriuso
#ESMOAsia25: Impressive results from the Chinese LUMINET-1 phase III trial confirm and extend previous findings with 177Lu-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumours (#GEP-NETs).
Read more in the #ESMODailyReporter ➡️https://ow.ly/mUuE50XEwSo
Read more in the #ESMODailyReporter ➡️https://ow.ly/mUuE50XEwSo
December 6, 2025 at 1:30 PM
#ESMOAsia25: Impressive results from the Chinese LUMINET-1 phase III trial confirm and extend previous findings with 177Lu-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumours (#GEP-NETs).
Read more in the #ESMODailyReporter ➡️https://ow.ly/mUuE50XEwSo
Read more in the #ESMODailyReporter ➡️https://ow.ly/mUuE50XEwSo
Reposted by Jorge Barriuso
📣 Registration for #ESMOTATAsia26 is open! Join global experts in #precisiononcology and discover the latest breakthroughs in cancer #drugdevelopment
🔗 https://ow.ly/oQRg50XBOZZ
⏰ Early Registration applies until 8 April 2026.
🔗 https://ow.ly/oQRg50XBOZZ
⏰ Early Registration applies until 8 April 2026.
December 4, 2025 at 11:00 PM
📣 Registration for #ESMOTATAsia26 is open! Join global experts in #precisiononcology and discover the latest breakthroughs in cancer #drugdevelopment
🔗 https://ow.ly/oQRg50XBOZZ
⏰ Early Registration applies until 8 April 2026.
🔗 https://ow.ly/oQRg50XBOZZ
⏰ Early Registration applies until 8 April 2026.
Reposted by Jorge Barriuso
In the #ESMODailyReporter, Eileen Yi Ling Poon discusses addressing the medical and psychosocial needs of adolescents and young adults (#AYA) w/ cancer, providing individualised treatment, targeted emotional support and age-appropriate information: https://ow.ly/O94S50XCBee
#ESMOAsia25
#ESMOAsia25
December 5, 2025 at 8:10 AM
In the #ESMODailyReporter, Eileen Yi Ling Poon discusses addressing the medical and psychosocial needs of adolescents and young adults (#AYA) w/ cancer, providing individualised treatment, targeted emotional support and age-appropriate information: https://ow.ly/O94S50XCBee
#ESMOAsia25
#ESMOAsia25
Reposted by Jorge Barriuso
🙌Today, we witnessed the power of togetherness at #ESMOAsia25. Crowded rooms, meaningful discussions, and groundbreaking research, all united by one mission: improving patient outcomes in Asia. #esmomeetings
👉 Together, we shape the future of oncology: buff.ly/qHVAi4F
👉 Together, we shape the future of oncology: buff.ly/qHVAi4F
December 5, 2025 at 10:01 AM
🙌Today, we witnessed the power of togetherness at #ESMOAsia25. Crowded rooms, meaningful discussions, and groundbreaking research, all united by one mission: improving patient outcomes in Asia. #esmomeetings
👉 Together, we shape the future of oncology: buff.ly/qHVAi4F
👉 Together, we shape the future of oncology: buff.ly/qHVAi4F
Reposted by Jorge Barriuso
#ESMOAsia25: The CLDN18.2-targeting antibody–drug conjugate (#ADC), JS107 in combination, achieved an impressive response rate in the first-line treatment of CLDN18.2-high #GastricCancer in a phase I #ClinicalTrial.
📌 Read more: https://ow.ly/MIw750XCBfZ
#ESMODailyReporter
📌 Read more: https://ow.ly/MIw750XCBfZ
#ESMODailyReporter
December 5, 2025 at 11:05 AM
#ESMOAsia25: The CLDN18.2-targeting antibody–drug conjugate (#ADC), JS107 in combination, achieved an impressive response rate in the first-line treatment of CLDN18.2-high #GastricCancer in a phase I #ClinicalTrial.
📌 Read more: https://ow.ly/MIw750XCBfZ
#ESMODailyReporter
📌 Read more: https://ow.ly/MIw750XCBfZ
#ESMODailyReporter
Reposted by Jorge Barriuso
ESMO is excited to announce the #ESMOMeritAward recipients, selected by the Congress Scientific Committee for the exceptional scientific merit of their abstracts. #ESMOAsia25
📌 https://ow.ly/tko150XCK64
📌 https://ow.ly/tko150XCK64
December 5, 2025 at 1:32 PM
ESMO is excited to announce the #ESMOMeritAward recipients, selected by the Congress Scientific Committee for the exceptional scientific merit of their abstracts. #ESMOAsia25
📌 https://ow.ly/tko150XCK64
📌 https://ow.ly/tko150XCK64
Reposted by Jorge Barriuso
#ESMOAsia25: Encouraging phase II findings were presented with the p53 reactivator, rezatapopt, in patients with heavily pre-treated solid tumours expressing the TP53 Y220C mutation.
📌Read more: https://ow.ly/htXy50XCCKL
#ESMODailyReporter
📌Read more: https://ow.ly/htXy50XCCKL
#ESMODailyReporter
December 5, 2025 at 3:15 PM
#ESMOAsia25: Encouraging phase II findings were presented with the p53 reactivator, rezatapopt, in patients with heavily pre-treated solid tumours expressing the TP53 Y220C mutation.
📌Read more: https://ow.ly/htXy50XCCKL
#ESMODailyReporter
📌Read more: https://ow.ly/htXy50XCCKL
#ESMODailyReporter
Reposted by Jorge Barriuso
Josephine Contreras-Tolentino discusses why acknowledging population diversity matters. As shown at #ESMOAsia25, ethnicity differences can impact on presentation and tolerability, which can influence treatment selection.
➡️Read more: https://ow.ly/161g50XEwRu
#ESMODailyReporter
➡️Read more: https://ow.ly/161g50XEwRu
#ESMODailyReporter
December 6, 2025 at 10:18 AM
Josephine Contreras-Tolentino discusses why acknowledging population diversity matters. As shown at #ESMOAsia25, ethnicity differences can impact on presentation and tolerability, which can influence treatment selection.
➡️Read more: https://ow.ly/161g50XEwRu
#ESMODailyReporter
➡️Read more: https://ow.ly/161g50XEwRu
#ESMODailyReporter
Reposted by Jorge Barriuso
People with a history of polyps often do not get follow-up colonoscopy after a positive FIT test, early-onset cancers are rising in Corn Belt states, and more. Read these stories and more from Cancer Today magazine's Week in Cancer News. www.cancertodaymag.org/cancer-talk/...
October 31, 2025 at 7:59 PM
People with a history of polyps often do not get follow-up colonoscopy after a positive FIT test, early-onset cancers are rising in Corn Belt states, and more. Read these stories and more from Cancer Today magazine's Week in Cancer News. www.cancertodaymag.org/cancer-talk/...
Reposted by Jorge Barriuso
#ESMO25: First evidence for the efficacy and safety of #TargetedTherapy in #mesothelioma reported as two novel TEAD inhibitors show clinical activity and manageable toxicity in heavily pre-treated patients.
📌Read more in the #ESMODailyReporter https://ow.ly/FARM50XkmWE
📌Read more in the #ESMODailyReporter https://ow.ly/FARM50XkmWE
October 30, 2025 at 5:01 PM
#ESMO25: First evidence for the efficacy and safety of #TargetedTherapy in #mesothelioma reported as two novel TEAD inhibitors show clinical activity and manageable toxicity in heavily pre-treated patients.
📌Read more in the #ESMODailyReporter https://ow.ly/FARM50XkmWE
📌Read more in the #ESMODailyReporter https://ow.ly/FARM50XkmWE
This is a really interesting piece of work if you are interested in spatial transcriptomics (ST).
👉 for single cell studies image based ST seems more appropriate
👉for spatial analysis of bigger regions sequencing based ST might be a better choice
www.nature.com/articles/s41...
👉 for single cell studies image based ST seems more appropriate
👉for spatial analysis of bigger regions sequencing based ST might be a better choice
www.nature.com/articles/s41...
Systematic benchmarking of high-throughput subcellular spatial transcriptomics platforms across human tumors - Nature Communications
This study benchmarks four cutting-edge spatial transcriptomics platforms using human tumour tissues, performs multi-metric evaluation with multi-omics references, and presents the SPATCH portal for v...
www.nature.com
October 25, 2025 at 9:46 AM
This is a really interesting piece of work if you are interested in spatial transcriptomics (ST).
👉 for single cell studies image based ST seems more appropriate
👉for spatial analysis of bigger regions sequencing based ST might be a better choice
www.nature.com/articles/s41...
👉 for single cell studies image based ST seems more appropriate
👉for spatial analysis of bigger regions sequencing based ST might be a better choice
www.nature.com/articles/s41...
Reposted by Jorge Barriuso
#ESMO25: Novel tissue-agnostic biomarker approaches utilising the latest technology, including cutting-edge #AI-driven #DigitalPathology, could improve #immunotherapy response through optimised patient selection.
More in the #ESMODailyReporter ➡️ https://ow.ly/smhA50XeYLq
More in the #ESMODailyReporter ➡️ https://ow.ly/smhA50XeYLq
October 20, 2025 at 5:30 PM
#ESMO25: Novel tissue-agnostic biomarker approaches utilising the latest technology, including cutting-edge #AI-driven #DigitalPathology, could improve #immunotherapy response through optimised patient selection.
More in the #ESMODailyReporter ➡️ https://ow.ly/smhA50XeYLq
More in the #ESMODailyReporter ➡️ https://ow.ly/smhA50XeYLq
Another outstanding discussion from Dra. Elena Élez on WSI H&Es AI used to predict response on the italian ATEZOTRIBE / AVATRIC cohorts and STELLAR-303.
👉 What about microbiome and tertiary lymphoid structures (TLS)
👉More translational studies needed
#ESMO25 @myesmo.bsky.social
👉 What about microbiome and tertiary lymphoid structures (TLS)
👉More translational studies needed
#ESMO25 @myesmo.bsky.social
October 20, 2025 at 8:14 AM
Another outstanding discussion from Dra. Elena Élez on WSI H&Es AI used to predict response on the italian ATEZOTRIBE / AVATRIC cohorts and STELLAR-303.
👉 What about microbiome and tertiary lymphoid structures (TLS)
👉More translational studies needed
#ESMO25 @myesmo.bsky.social
👉 What about microbiome and tertiary lymphoid structures (TLS)
👉More translational studies needed
#ESMO25 @myesmo.bsky.social
An amazing discussion by Dr Sharlene Gill on the updates of CHECKMATE 8HW and BREAKWATER.
👉 Can we identify patients deriving benefit from single agent IO in MMRd /MSI-H metastatic CRC?
👉Is there any room to rechallenge in BRAF mCRC?
#ESMODailyReporter @myesmo.bsky.social
👉 Can we identify patients deriving benefit from single agent IO in MMRd /MSI-H metastatic CRC?
👉Is there any room to rechallenge in BRAF mCRC?
#ESMODailyReporter @myesmo.bsky.social
October 20, 2025 at 7:58 AM
An amazing discussion by Dr Sharlene Gill on the updates of CHECKMATE 8HW and BREAKWATER.
👉 Can we identify patients deriving benefit from single agent IO in MMRd /MSI-H metastatic CRC?
👉Is there any room to rechallenge in BRAF mCRC?
#ESMODailyReporter @myesmo.bsky.social
👉 Can we identify patients deriving benefit from single agent IO in MMRd /MSI-H metastatic CRC?
👉Is there any room to rechallenge in BRAF mCRC?
#ESMODailyReporter @myesmo.bsky.social
Reposted by Jorge Barriuso
🎥 50 years of key moments.
ESMO’s 50th anniversary marks decades of achievements in #ScienceDissemination, #education and #collaboration. Take a selfie and share one of your milestones with #myESMOStory. #ESMO25
🔗 www.youtube.com/watch?v=dJTH...
ESMO’s 50th anniversary marks decades of achievements in #ScienceDissemination, #education and #collaboration. Take a selfie and share one of your milestones with #myESMOStory. #ESMO25
🔗 www.youtube.com/watch?v=dJTH...
October 19, 2025 at 1:49 PM
🎥 50 years of key moments.
ESMO’s 50th anniversary marks decades of achievements in #ScienceDissemination, #education and #collaboration. Take a selfie and share one of your milestones with #myESMOStory. #ESMO25
🔗 www.youtube.com/watch?v=dJTH...
ESMO’s 50th anniversary marks decades of achievements in #ScienceDissemination, #education and #collaboration. Take a selfie and share one of your milestones with #myESMOStory. #ESMO25
🔗 www.youtube.com/watch?v=dJTH...
Reposted by Jorge Barriuso
#ESMO25: Clinically relevant survival benefits reported in platinum-resistant #OvarianCancer with pembrolizumab plus weekly paclitaxel with or without bevacizumab in ENGOT-ov65/KEYNOTE-B96 #ESMODailyReporter 👉https://ow.ly/MIjA50XeuR3
#immunotherapy
#immunotherapy
October 18, 2025 at 4:01 PM
#ESMO25: Clinically relevant survival benefits reported in platinum-resistant #OvarianCancer with pembrolizumab plus weekly paclitaxel with or without bevacizumab in ENGOT-ov65/KEYNOTE-B96 #ESMODailyReporter 👉https://ow.ly/MIjA50XeuR3
#immunotherapy
#immunotherapy
Deeply honoured for participating in #ESSO44 Gothenburg as speaker in the session Progress in Pseudomyxoma Peritonei Therapy! @essonews.bsky.social
To Berlin now for an exciting #ESMO25 @myesmo.bsky.social #ESMODailyReporter
and shortly see you at PSOGI meeting in Barcelona
To Berlin now for an exciting #ESMO25 @myesmo.bsky.social #ESMODailyReporter
and shortly see you at PSOGI meeting in Barcelona
October 16, 2025 at 1:43 PM
Deeply honoured for participating in #ESSO44 Gothenburg as speaker in the session Progress in Pseudomyxoma Peritonei Therapy! @essonews.bsky.social
To Berlin now for an exciting #ESMO25 @myesmo.bsky.social #ESMODailyReporter
and shortly see you at PSOGI meeting in Barcelona
To Berlin now for an exciting #ESMO25 @myesmo.bsky.social #ESMODailyReporter
and shortly see you at PSOGI meeting in Barcelona
Much needed collaboration between @myesmo.bsky.social and ESTRO !
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors - Annals of Oncology www.annalsofoncology.org/article/S092...
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors - Annals of Oncology www.annalsofoncology.org/article/S092...
October 4, 2025 at 4:14 PM
Much needed collaboration between @myesmo.bsky.social and ESTRO !
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors - Annals of Oncology www.annalsofoncology.org/article/S092...
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors - Annals of Oncology www.annalsofoncology.org/article/S092...